CRSP
CRISPR Therapeutics AG
Stock
$55.43−0.01 (−0.02%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$370M | −$345M | −$143M | −$260M | −$496M | $539M | −$238M | $57M | −$96M | −$70M | −$53M | $59M | −$4.8M |
| Capital expenditures | $1.7M | $914K | $1.9M | $9.5M | $37M | $82M | $18M | $6.7M | $2.8M | $7.8M | $3.0M | $1.2M | — |
| Free cash flow | −$371M | −$346M | −$145M | −$270M | −$533M | $457M | −$257M | $50M | −$99M | −$78M | −$56M | $58M | — |
| Stock-based compensation | $68M | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $3.7M | $695K |
| Buybacks | — | — | — | — | — | — | — | — | $57K | — | — | — | — |
| Free cash flow margin | −2,772.7% | −9,855.5% | −387.7% | −72.7% | −44,484.9% | 50.0% | −35,705.7% | 17.3% | −3,169.4% | −190.0% | −1,082.0% | 23,592.7% | — |